Novel immunotherapy combo featured in new trial for recurrent glioblastoma
October 10, 2019 | By
Letisia Marquez
City of Hope has opened a first-in-human clinical trial for patients with recurrent glioblastoma – the trial is the first to combine City of Hope’s unique CAR T cell therapy with immune checkpoint inhibitors.
Research
|
Patient Care